Trial Profile
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms ENESTnext
- Sponsors Novartis; Novartis Pharmaceuticals
- 06 Feb 2016 Patients are now permitted, per Investigator's discretion, increased dose of nilotinib 400 b.i.d as per ClinicalTrials.gov record.
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 05 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.